Where does Caroline Haegeman work?

Caroline Haegeman is Associate at Delin Ventures.

Where did Caroline Haegeman go to school?

Caroline Haegeman studied at Imperial College London (Doctor of Philosophy - PhD, Oncology and Cancer Biology); UCL (Master of Science (MSc), Drug Discovery and Development); Imperial College London (Bachelor of Science (B.Sc. Hons), Biochemistry).

Caroline Haegeman

Investor

Associate at Delin Ventures

New York, New York, United States

Find your path to Caroline

27 people in our graph share verified history with Caroline — schools, employers, funds. One of them is your warm intro.

Isabel ZhangunlockedCaroline: together at Panacea Innovation (2020)

Caroline: together at Panacea Innovation

×10Caroline: together at Delin Ventures

About

Caroline Haegeman is Co-Founder and Chief Operating Officer of Athernal Bio, a company developing immunotherapies targeting high-risk clonal hematopoiesis, a precursor to acute myeloid leukemia. She holds a PhD in Oncology from Imperial College London and previously worked at Boston Consulting Group advising pharmaceutical and biotech companies on R&D and clinical strategy, and as a biotech investor at Delin Ventures. At Athernal, her responsibilities include corporate and capital strategy, cross-functional execution of preclinical programs, and advisor engagement.

Contact· self-published, not guessed

c•••@delinventures.comreveal

Experience

Athernal BioCo-Founder, Chief Operating Officer (COO)current2024 — presentCambridge, England, United Kingdom
IMMvention Therapeutix, Inc.Board Observercurrent2023 — present
Delin VenturesSenior Investment Associate2025London Area, United Kingdom
Delin VenturesInvestment Associate2023 — 2024Greater London, England, United Kingdom
Boston Consulting Group (BCG)Senior Associate2022 — 2023Greater London, England, United Kingdom
Box42 DatesDirector and Co-Founder2020 — 2023Greater London, England, United Kingdom
Panacea InnovationPortfolio Manager & Consultant2020
Panacea InnovationProgramme Principal2019 — 2020
Panacea InnovationProgramme Lead2019Greater Oxford Area

Skills & more

Microsoft PowerPointResearch SkillsTherapeuticsDealsDue DiligenceMarket ResearchBiotechnologyCommercial DevelopmentStrategisingVenture CapitalPortfolio ManagementInvestments

+12 more

Organization SkillsMicrosoft ExcelTeamworkDrug DiscoveryClinical TrialsTechnical WritingBiochemistryEntrepreneurshipTeachingCancer BiologyScience CommunicationLeadership

Languages Dutch · English · French

Science and Technology Venture Capitalist Fellowship — Royal Academy of Engineering

From Caroline's professional profile.

Colleagues at Delin Ventures

Alan Barge

Venture Partner at Delin Ventures

Carol Lynch

Advisor at Delin Ventures

Christopher Spray

Advisor at Delin Ventures

Colin Sims

Partner at Delin Ventures

Igor Linshits

Founder at Delin Ventures

İskender Dirik

Partner at Delin Ventures

Jakub Czarnecki

Financial Controller at Delin Ventures

John Campbell

EIR at Delin Ventures

Frequently asked questions

Who is Caroline Haegeman?: Caroline Haegeman is Co-Founder and Chief Operating Officer of Athernal Bio, a company developing immunotherapies targeting high-risk clonal hematopoiesis, a precursor to acute myeloid leukemia. She holds a PhD in Oncology from Imperial College London and previously worked at Boston Consulting Group advising pharmaceutical and biotech companies on R&D and clinical strategy, and as a biotech investor at Delin Ventures. At Athernal, her responsibilities include corporate and capital strategy, cross-functional execution of preclinical programs, and advisor engagement.
Where does Caroline Haegeman work?: Caroline Haegeman is Associate at Delin Ventures.
Where did Caroline Haegeman go to school?: Caroline Haegeman studied at Imperial College London (Doctor of Philosophy - PhD, Oncology and Cancer Biology); UCL (Master of Science (MSc), Drug Discovery and Development); Imperial College London (Bachelor of Science (B.Sc. Hons), Biochemistry).

Same school

Also attended Imperial College London824

Deji SasegbonVP, Platform & Portfolio Operations at EchoVC Partners Madison LenormandInvestor at Daphni Loubaba El AyoubiInvestor at Northzone Giovanni MariggiInvestor at Medicxi Francois PrinslooInvestor at Medicxi Ben PerryInvestor at Medicxi

+ 818 more

Also attended UCL706

Demis HassabisCo-founder & CEO of Google DeepMind André DuboisInvestor at Index Ventures Frédérique DameInvestor at GV (Google Ventures)Jonas VetterleInvestor at Moonfire Ventures Marie FerriInvestor at Daphni Elena PantaziPartner & Head of Platform at Northzone

+ 700 more

Shared employers

Also worked at IMMvention Therapeutix, Inc.3

Rosie BarnettPrincipal at Delin Ventures Ben ScruggsPartner at Hatteras Venture Partners Matt CohenManaging Partner at OUP (Osage University Partners)

Also worked at Delin Ventures12

Igor LinshitsFounder at Delin Ventures Jonathan HayPartner at Delin Ventures Carol LynchAdvisor at Delin Ventures Iskender DirikPartner at Delin Ventures Rosie BarnettPrincipal at Delin Ventures Matt SymesInvestor at Delin Ventures

+ 6 more

Also worked at Boston Consulting Group (BCG)1,469

Cristina JunqueiraCo-founder of Nubank Massimo PrelzInvestor at DN Capital Rasmus AreskougInvestor at DN Capital Riccardo MontiOperating Advisor at P101 Ventures Antonio TurroniOperating Advisor at P101 Ventures Luca RossettoOperating Advisor at P101 Ventures

+ 1,463 more

Also worked at Panacea Innovation7

Isabel ZhangInvestor at HCVC Robert ThongCo-Founder & General Partner at Selvedge Venture Eleanor PriceAssociate at Thuja Capital Annelies FeeneyExecutive Assistant at Wamda Capital Marc-Olivier TurgeonSenior Associate at Forbion Afshin MoayedCo-Founder & Managing Partner at Razor Capital

+ 1 more